---

GOOD MORNING BREAKFAST

---

OPENING ADDRESS 

• DCAT Executive Board Member  

---

MASTER OF CEREMONIES 

• West Pharmaceutical Services, Inc., Stacey Vaughan, VP Marketing & Portfolio Management 

---

SESSION III: ADVANCED THERAPIES & BIOLOGICS – ACCELERATING DEVELOPMENT WITH NEXT-GENERATION MANUFACTURING 

This session highlights how leading companies are advancing the development and production of biologics and advanced therapies by leveraging integrated platforms, digital infrastructure, and flexible manufacturing models. The presentations spotlight technologies that reduce development timelines, improve scalability, and enable precision-targeted treatments in oncology and beyond. 

• Made Scientific, David Smith, VP and Head of Development  
• Eli Lilly & Company, Jesus Castanon, Sr. Director, Discovery Chemistry  
• Axplora, Arul Ramadurai, Chief Commercial Officer 
• enGene, Anthony T. Cheung, Ph.D., Chief Scientific Officer 

Presenters will explore how manufacturing innovation, digital connectivity, and patient-focused design are converging to transform the advanced therapies landscape—accelerating time to market while maintaining safety, consistency, and clinical impact. 

Session III: Moderated Panel Discussion 

• Moderator:
  • Made Scientific, Syed Husain, Chief Executive Officer 
• Panelists:
  • Made Scientific, David Smith, VP and Head of Development  
  • Eli Lilly & Company, Jesus Castanon, Sr. Director, Discovery Chemistry  
  • Axplora, Arul Ramadurai, Chief Commercial Officer 
  • enGene, Anthony T. Cheung, Ph.D., Chief Scientific Officer  

---

MORNING NETWORKING REFRESHMENTS

---

KEYNOTE 2: DR. MOHAMED ABURAWI, INNOVATING FOR IMPACT

Dr. Mohamed Aburawi, a Libya-born surgeon and tech entrepreneur, is the founder and CEO of Atarona Ventures, where he leads the creation and scaling of transformational, high-impact ventures across global health, education, financial inclusion, and energy access. Passionate about bold ideas that accelerate social progress, Mohamed’s work is dedicated to minimizing suffering and fostering inclusive prosperity for the next billion people in some of the world’s most impoverished regions. 

Focusing on his native Libya, Dr. Aburawi explores how technology can dismantle barriers to quality care and promote health care as a fundamental human right. Aburawi is a visionary entrepreneur committed to transforming healthcare accessibility and education in regions facing conflict and economic challenges.  

Through initiatives like Speetar, he aims to establish resilient care systems that provide immediate medical services and empower communities for sustainable development. His focus on supporting vulnerable groups like women and children in crisis situations underscores his commitment to equitable healthcare and education opportunities. 

By leveraging innovative technology and forging global partnerships, Mohamed strives to ensure that every individual has the chance to thrive, irrespective of their circumstances. His work embodies a mission to ensure universal access to healthcare. and education a reality worldwide. 

Moderated Q&A: Dr. Aburawi

• Moderator: 
  • DCAT Executive Board Member 

---

LUNCHEON

---

SESSION IV: TRANSFORMING DRUG FORMULATION: ENHANCING SOLUBILITY, PATIENT COMPLIANCE AND MANUFACTURING SUSTAINABILITY 

This session explores groundbreaking advances in drug formulation that improve the solubility of poorly soluble drugs, streamline dosage forms, and enhance patient compliance—particularly for populations with swallowing difficulties or multiple comorbidities. With nearly 70% of drugs in development exhibiting low solubility, the need for novel delivery approaches has never been greater. 

• Nanoform, Christian Jones, Chief Commercial Officer
• NanoPharma Solutions, Kay Olmstead, Chief Executive Officer
• dsm-firmenich, Athanasia Kanli, Senior Director, Marketing & Business Development Manager

Presenters will address the technological, regulatory, and patient-centric drivers behind these innovations and share insights into the financial outcomes, scalability, and lifecycle management of new and mature products. 

Session IV: Moderated Panel Discussion 

• Moderator: 
  • dsm-firmenich, Kelsey Achenbach, VP Pharmaceutical Business & DCAT First Vice President 
• Panelists:
  • Nanoform, Christian Jones, Chief Commercial Officer 
  • NanoPharma Solutions, Kay Olmstead, Chief Executive Officer  
  • dsm-firmenich, Athanasia Kanli, Senior Director, Marketing & Business Development Manager

---

AFTERNOON NETWORKING REFRESHMENTS

---

CAPSTONE PANEL: CREATING PATIENT VALUE IN A MISALIGNED WORLD 

In today’s rapidly shifting global landscape, stakeholder expectations, regulatory frameworks, geopolitical forces and healthcare access are becoming increasingly disconnected. How can the industry realign its efforts to create meaningful, sustainable value for patients? The Summit’s capstone panel tackles this urgent question head-on, bringing together a powerhouse group of 4-5 thought leaders for a dynamic, cross-cutting discussion that ties together the most critical themes explored throughout the program. Topics on the table include drug pricing and affordability, the evolving regulatory environment (including the EU Medicines Act and U.S. PILL Act), the impact of tariffs on branded and generic therapies, global access challenges, supply chain vulnerabilities, and the transformative influence of AI. 

This can’t-miss session goes beyond identifying problems. It will challenge assumptions, spotlight tensions between commercial imperatives and patient outcomes, and uncover opportunities for innovation. Join the conversation and leave inspired, informed, and better equipped to drive real patient-centered change in an increasingly complex business ecosystem. 

• Moderator:
  • Eli Lilly and Company, Michael Semo, Associate Vice President, External Sourcing & DCAT Third Vice President 
• Panelists:
  • Icrom, Pierfrancesco Morosini, Chief Executive Officer & DCAT Director 
  • Panelists will be announced as commitments are received

---

CLOSING KEYNOTE: MR. BENJAMIN HALL, VETERAN WAR CORRESPONDENT

A veteran war correspondent, Mr Hall was critically injured while reporting on the front lines in Ukraine when a multi-sequential rocket attack struck him and his team. Tragically, two members of his crew – cameraman Pierre Zakrewski and journalist Oleksandra “Sasha” Kuvshinova- lost their lives. Mr. Hall’s survival was uncertain, and his journey forward became a testament to resilience, global collaboration, and the unwavering power of innovation in patient care.  

Mr. Halls’s story exemplifies the very essence of a patient-first mindset. His recovery was made possible by the extraordinary efforts of medical teams, technological advances and the human spirit. He will share his inspiring account of survival and the role that courage, science and compassionate care played in his path to healing. 

His powerful message reminds us why innovation, inspiration and transformation are critical to the future of the global bio/pharmaceutical industry – and why the work we do matters.  

---

CLOSING KEYNOTE Q&A 

• Moderator: 
  • Lone Fox Endeavors, Donna Gruol, President and Founder & DCAT President 

---

CLOSING REMARKS & THANK YOU 

• Mrs. Donna Gruol, DCAT President & Summit at Lugano Task Force Chairperson  

---

NETWORKING COCKTAIL & DINNER RECEPTION 

Location:
Hotel Splendide Royal Lugano
Riva Antonio Caccia 7
6900 Lugano, Switzerland